IgA肾病的支持治疗及进展  

Supportive treatment and its progress of IgA nephropathy

作　　者：禹丹 张军军[1] YU Dan;ZHANG Jun-jun(Department of Nephrology,The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)

机构地区：[1]郑州大学第一附属医院肾脏内科,河南郑州450052

出　　处：《实用医院临床杂志》2024年第1期26-30,共5页Practical Journal of Clinical Medicine

基　　金：国家自然科学基金资助项目(编号:82170721)。

摘　　要：IgA肾病是我国最常见的原发性肾小球疾病之一,目前IgA肾病的治疗包括支持治疗和免疫抑制治疗,而支持治疗是IgA肾病治疗的基石。改善全球肾脏病预后组织(KDIGO)肾小球疾病管理临床实践指南建议的支持治疗包括优化生活方式、血压管理、充分RAAS阻断以及评估并干预心血管事件风险等。本文就IgA肾病的支持治疗及进展进行综述。IgA nephropathy is one of the most common primary glomerular diseases in China.At present,the treatment of IgA nephropathy includes supportive treatment and immunosuppressive treatment.The supportive treatment is the cornerstone of the treatment of the disease.The clinical practice guidelines of Kidney Disease Improving Global Outcomes(KDIGO)suggests that the supportive treatment includes lifestyle modification,blood pressure management,sufficient blockade of renin-angiotensin-aldosterone system(RAAS),as well as assessment and intervention of cardiovascular risk.This article reviews the supportive treatment and its progress of IgA nephropathy.

关 键 词：IGA肾病 支持治疗 KDIGO肾小球疾病管理临床实践指南 

分 类 号：R692.6[医药卫生—泌尿科学]